Press Release FeedGet the RSS feed
Menu

GlobeNewswire

BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie

Bristol-Myers Squibb

MAINZ, Deutschland und PRINCETON, USA, 25. Oktober 2026 – BioNTech SE (Nasdaq: BNTX, „BioNTech“) und Bristol Myers Squibb Company (NYSE: BMY, „BMS“) gaben heute erste Daten aus der globalen klinischen Phase-2-Studie ROSETTA Lung-107 (NCT06841055) bekannt. In der Studie wird der bispezifische PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig (BNT327/BMS986545) in Kombination mit Docetaxel bei Patientinnen und Patienten mit metastasiertem nicht-kleinzelligem Lungenkrebs (non-small cell lung cancer, „NSCLC“) untersucht, deren Erkrankung während oder nach einer Erstlinienbehandlung mit Immuntherapie plus Chemotherapie fortgeschritten ist.

  1. Biotech & pharmaBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyCompanies: Bristol-Myers SquibbPumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or after immunotherapy plus chemotherapy An early median progression-free survival of 6.9 months was observed Significant unmet need remains for patients who have progressed on an … Continue reading "BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy"
  2. FinanceBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyCompanies: Bristol-Myers SquibbMAINZ, Germany, and — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy.
  3. FinanceBristol Myers SquibbBristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026Companies: Bristol-Myers SquibbData reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis PRINCETON, N.J., October 23, 2026--Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohort
  4. AIPathos AIPathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological ConditionsCompanies: Bristol-Myers SquibbTempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos's AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb's (BMS) neuroscience drug development expertise to b
  5. FinanceTempus AI, Inc.Tempus Expands Strategic Collaboration with Bristol Myers SquibbCompanies: Bristol-Myers SquibbCHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug ta
  6. HealthcareThe Institute for Healthcare ImprovementIHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical TrialsCompanies: Bristol-Myers SquibbThree-year initiative will bring clinical research closer to patients and address barriers to trial participation BOSTON, October 22, 2026--The Institute for Healthcare Improvement (IHI), in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative. This thr